SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, has announced its fiscal 2025 second-quarter financial results, highlighting strategic investments and operational resilience despite a challenging macroeconomic environment. The company reported a revenue increase of 4.5% year-over-year, driven by organic growth, currency-neutral revenues, and a focus on operational efficiency.
BD's continued commitment to innovation and market leadership is evident as it invests in manufacturing capacity and product advancements across its key segments. This article delves into the company’s financial performance, strategic initiatives, and future growth outlook, underlining its position as a driving force in the global healthcare market.
Strong Financial Results and Strategic Investments
For the second quarter of fiscal 2025, BD posted revenues of $5.3 billion, a 4.5% increase from the same period in 2024. This growth reflects a robust 6.0% currency-neutral performance and a 0.9% increase in organic revenue. Despite the tough operating environment, the company exceeded earnings expectations, reporting adjusted diluted earnings per share (EPS) of $3.35, a 5.7% increase from last year.
“We are seeing the strength of our business model, driven by BD Excellence, which is enabling continued margin expansion,” said Tom Polen, Chairman, CEO, and President of BD. “Our investments in commercial capabilities, innovation, and the BD Excellence operating system are positioning us to accelerate growth as global markets recover.”
In a significant strategic move, BD announced plans to invest $2.5 billion in U.S. manufacturing over the next five years. This initiative is aimed at reinforcing BD’s position as the largest U.S. manufacturer of medical devices, ensuring a resilient healthcare supply chain, and supporting future growth.
Segment Performance and Key Business Highlights
BD’s performance in its medical technology and healthcare segments reflects strong demand and innovation-driven growth, particularly in BD Medical and BD Interventional.
BD Medical
- BD Medical’s revenue rose 12.7%, driven by solid demand in medication delivery systems, infusion solutions, and advanced patient monitoring.
- The Medication Management Solutions (MMS) unit saw double-digit growth in infusion solutions, with the BD Alaris™ Infusion System receiving notable recognition.
- The company also launched the HemoSphere Alta™ Advanced Monitoring Platform, which integrates AI-driven clinical decision support, signaling BD's commitment to advancing patient care.
BD Interventional
- BD Interventional reported a slight revenue decline of 2.2%, impacted by an outsized prior-year comparison in Urology & Critical Care. However, the Surgery division achieved strong growth, particularly in the Phasix™ hernia resorbable scaffold.
- The approval of the FDA 510(k) clearance for the Phasix™ ST Umbilical Hernia Patch marks a key milestone for BD in expanding its interventional portfolio.
BD Life Sciences
- BD Life Sciences faced challenges, with a 4.3% revenue decline. The Diagnostic Solutions business unit, in particular, was affected by slower-than-expected testing volumes following supply disruptions. However, the BD MAX™ IVD platform and continued growth in specimen management provided some resilience.
- BD Life Sciences has made notable strides in antimicrobial resistance detection, receiving FDA 510(k) clearance for its integrated microbiology solution, combining BD Phoenix™, BDXpert™, and BD Synapsys™ Informatics solutions.
Full-Year Outlook and Strategic Guidance
Looking ahead, BD updated its full-year fiscal 2025 guidance. The company now expects revenues to range between $21.8 billion and $21.9 billion, reflecting organic revenue growth of 3.0% to 3.5%. Despite a challenging global environment, BD anticipates strong operational performance to offset tariff impacts, with adjusted diluted EPS projected to be between $14.06 and $14.34, representing a year-over-year growth of 7.0% to 9.1%.
Polen further commented, “While the macroeconomic environment remains challenging, we are confident that our diversified portfolio, strategic investments, and continued focus on operational excellence will position us for long-term value creation and growth.”
Conclusion
BD’s second-quarter results for fiscal 2025 demonstrate the company’s resilience in a dynamic market, with strong revenue growth, margin improvements, and strategic investments in innovation and manufacturing. As BD continues to expand its capabilities across its core medical technology segments, the company remains well-positioned to capitalize on market opportunities and drive sustainable growth in the healthcare sector.
For more information on BD’s ongoing initiatives and product offerings, visit www.bd.com.